Explore how EZH2 inhibition fights multiple myeloma by targeting epigenetic modifications, restoring cell cycle control, and overcoming high-risk disease features.
Exploring EZH2's role as a prognostic biomarker and therapeutic target in non-small cell lung cancer through meta-analyses and bioinformatics.